Introduction For decades, the field of hepatology faced a glaring therapeutic void. Metabolically-dysfunction-associated steatohepatitis (MASH), formerly and still widely known as Non-Alcoholic Steatohepatitis (NASH), affects millions globally, driving a rising tide of cirrhosis, liver failure, and hepatocellular carcinoma. Despite its prevalence, affecting an estimated 5.3% of the global adult population, it has earned a reputation as a "graveyard" for pharmaceutical develop

You've just had a check-up with your doctor and the decision was made to start you on a new medication. Or maybe you've been discharged from the hospital and have been given a whole LIST of new medications to take. All you want to do is go home. The instructions are on the bottle. You don't need to know anything else...right? WRONG! Your doctor or pharmacist should be telling you all the nitty-gritty details about your new medication. If not, make sure to ask these questions!

Introduction Small-cell lung cancer (SCLC) is one of the most aggressive and difficult-to-treat forms of cancer, characterized by rapid growth and early metastasis. For decades, patients who progressed after initial platinum-based chemotherapy faced poor prognoses and limited treatment options, often relying on older chemotherapy agents with modest efficacy and high toxicity. This landscape shifted significantly on November 19, 2025, when the U.S. Food and Drug Administration

Introduction Obesity is a chronic disease associated with reduced quality of life and increased mortality, yet effective treatment options remain logistically challenging for many patients. While Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of obesity and Type 2 diabetes, they are predominantly peptide-based drugs administered via subcutaneous injection. The production complexities and administration discomfort associated with injec